Pfizer NZ is honoured is to be chosen as the New Zealand Government’s primary vaccine provider

Pfizer has entered into an agreement with the New Zealand government to provide 8.5 million additional doses of its mRNA vaccine COMIRNATY.

Pfizer is committed to supply 10 million doses of the vaccine to New Zealand over the course of 2021.

Pfizer will work closely with the Government to support their vaccine implementation plan for New Zealanders.

Allocation of doses and implementation plan within a country is a decision for governments based on relevant health authority guidance.

Anne Harris, Managing Director, Australia & New Zealand said: “Pfizer is pleased to supply an additional 8.5 million doses of our mRNA-based vaccine, COMIRNATY to the New Zealand Government to support their COVID-19 vaccination program.

“This decision recognises that COMIRNATY has met Medsafe’s strict standards for safety, efficacy and quality.

“Pfizer is honoured is to be chosen as the New Zealand Government’s primary vaccine provider.

“We are committed to providing 10 million doses of our vaccine over the course of 2021 to help protect New Zealanders from COVID-19.

“Pfizer and BioNTech have mounted an extraordinary response to the global pandemic. Based on current projections, we are now targeting capacity of approximately 2 billion doses in total by the end of 2021, up from 1.3 billion doses.”

Pfizer and BioNTech previously announced on 12 October 2020 an agreement with the New Zealand Government to supply 1.5 million doses of its mRNA-based vaccine COMIRNATY™ to 750,000 New Zealanders, once approved. Dose deliveries will occur throughout 2021 in accordance with terms of the supply agreement.

To date, the vaccine has been granted a conditional marketing, emergency use authorisation or temporary authorisation in more than 50 countries worldwide.

Manufacturing and Delivery Capabilities

Pfizer and BioNTech continue to work in collaboration with governments and Ministries of Health around the world that will distribute the vaccine, subject to country authorisation or approval, to help ensure it can reach those most in need as quickly as possible. The companies are leveraging leading vaccine manufacturing and distribution capabilities to quickly scale, manufacture and distribute large quantities of the vaccine at high quality, complementing the mRNA manufacturing expertise of BioNTech gained over almost a decade. Pfizer has a 171-year track record of researching, developing, manufacturing and delivering innovative medicines and vaccines to patients in need.

About Pfizer: Breakthroughs That Change Patients’ Lives

At Pfizer, we apply science and our global resources to bring therapies to people that extend and significantly improve their lives. We strive to set the standard for quality, safety and value in the discovery, development and manufacture of health care products, including innovative medicines and vaccines. Every day, Pfizer colleagues work across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases of our time. Consistent with our responsibility as one of the world's premier innovative biopharmaceutical companies, we collaborate with health care providers, governments and local communities to support and expand access to reliable, affordable health care around the world. For more than 150 years, we have worked to make a difference for all who rely on us. We routinely post information that may be important to investors on our website at www.Pfizer.com. In addition, to learn more, please visit us on www.Pfizer.com and follow us on Twitter at @Pfizer and @Pfizer News, LinkedIn, YouTube and like us on Facebook at Facebook.com/Pfizer

Click here to subscribe